These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17650053)

  • 1. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents.
    Buckley PF
    J Clin Psychiatry; 2007; 68 Suppl 6():5-9. PubMed ID: 17650053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes.
    Lambert TJ
    J Clin Psychiatry; 2007; 68 Suppl 6():10-3. PubMed ID: 17650054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of neuroleptics in use in the United States.
    Richelson E
    J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):8-14. PubMed ID: 2862140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.
    Weiden PJ; Buckley PF
    J Clin Psychiatry; 2007; 68 Suppl 6():14-23. PubMed ID: 17650055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
    Richelson E
    J Clin Psychiatry; 1984 Aug; 45(8):331-6. PubMed ID: 6146602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic drugs: prediction of side-effect profiles based on neuroreceptor data derived from human brain tissue.
    Black JL; Richelson E
    Mayo Clin Proc; 1987 May; 62(5):369-72. PubMed ID: 2883343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotics and newer antidepressants.
    Reilly TH; Kirk MA
    Emerg Med Clin North Am; 2007 May; 25(2):477-97; abstract x. PubMed ID: 17482029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics.
    Correll CU
    Eur Psychiatry; 2010 Jun; 25 Suppl 2():S12-21. PubMed ID: 20620881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain.
    Kanba S; Yagi G; Oguchi E; Nakaki T; Kato R; Richelson E
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):133-4. PubMed ID: 1684393
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching in the era of atypical antipsychotics. An updated review.
    Weiden PJ
    Postgrad Med; 2006 Sep; Spec No():27-44. PubMed ID: 17128659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study focuses in on potential cause of antipsychotic-induced diabetes.
    O'Neill MF
    Drug News Perspect; 2005 Oct; 18(8):481-2. PubMed ID: 16391716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.
    Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
    Prog Brain Res; 2008; 172():155-75. PubMed ID: 18772032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
    Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical stakes when switching from one antipsychotic to another].
    Constant É
    Encephale; 2013 Dec; 39(6):439-44. PubMed ID: 24238644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.
    Cerovecki A; Musil R; Klimke A; Seemüller F; Haen E; Schennach R; Kühn KU; Volz HP; Riedel M
    CNS Drugs; 2013 Jul; 27(7):545-72. PubMed ID: 23821039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase.
    Montastruc F; Palmaro A; Bagheri H; Schmitt L; Montastruc JL; Lapeyre-Mestre M
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1556-65. PubMed ID: 26256010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
    O'Keane V
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of bipolar disorder with antipsychotic medication: issues shared with schizophrenia.
    Young AH
    J Clin Psychiatry; 2007; 68 Suppl 6():24-5. PubMed ID: 17650056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.